BFM
NVIV

Boston Financial Management’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Boston Financial Management’s Portfolio NVIV Stock Details NVIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1
Closed -$8K – 277
2018
Q1 		$8K Sell
1
-1
-50% -$11.2K ﹤0.01% 264
2017
Q4 		$33K Sell
2
-1
-33% -$23.1K ﹤0.01% 261
2017
Q3 		$72K Hold
3
– – 0.01% 257
2017
Q2 		$133K Hold
3
– – 0.01% 268
2017
Q1 		$250K Sell
3
-1
-25% -$80.8K 0.02% 243
2016
Q4 		$312K Hold
4
– – 0.02% 232
2016
Q3 		$504K Hold
4
– – 0.04% 199
2016
Q2 		$429K Buy
+4
New +$470K 0.04% 199

Other funds holding NVIV

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
ICM
IMS Capital Management Portland, Oregon $217M AUM 18.69% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Boston Financial Management's NVIV Position: Q2 2018 in Review

Boston Financial Management sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q2 2018, closing a stake of 1 share — an estimated $8K sold.

Boston Financial Management first reported a position in NVIV in Q2 2016 and held it in 8 quarters. The position peaked at $504K in Q3 2016. 17 funds tracked by Wall St. Rank hold NVIV as of Q2 2018.

  • Boston Financial Management reported no remaining InVivo Therapeutics Holdings Corp position as of Q2 2018 after selling out during the quarter.
  • Boston Financial Management sold 1 InVivo Therapeutics Holdings Corp share in Q2 2018, an estimated $8K.
  • Boston Financial Management first reported a position in InVivo Therapeutics Holdings Corp in Q2 2016 and held it in 8 quarters.
  • Boston Financial Management's InVivo Therapeutics Holdings Corp position peaked at $504K in Q3 2016.
  • 17 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q2 2018.

Based on Boston Financial Management's 13F filing for Q2 2018, filed 3 Aug 2018.